Breast cancer is the most common cancer and the leading cause of morbidity and mortality among women worldwide.[1] Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, accounting for 15–20% of this malignancy.[2, 3] The lack of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression in TNBC means that conventional therapies targeting these receptors, such as hormone therapy and HER2‐targeted therapies, are not effective. Here, ERBB2 is linked to breast cancer.